Advice

following an abbreviated submission:

buprenorphine/naloxone sublingual film (Suboxone®) is accepted for restricted use within NHSScotland.

Indication under review: substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Buprenorphine/naloxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

SMC restriction: to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.

Buprenorphine/naloxone sublingual film (Suboxone®) and buprenorphine/naloxone sublingual tablets (Suboxone®) deliver similar plasma concentrations of buprenorphine but are not bioequivalent. Please refer to the relevant Summary of Product Characteristics for further detail, including guidance on switching between formulations.

Generic buprenorphine sublingual tablets are available at lower cost.

Download detailed advice726KB (PDF)

Download

Medicine details

Medicine name:
buprenorphine/naloxone (Suboxone)
SMC ID:
SMC2316
Indication:

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Pharmaceutical company
Indivior UK Limited
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published
08 February 2021